Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
:GILD
GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$82.82 - $121.83
Previous CloseN/A
Volume1.95M
Average Volume (3M)6.18M
Market Cap
$139.09B
Enterprise Value$157.48B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$24.95B
Price to Earnings (P/E)22.3
Beta0.40
Next Earnings
Oct 23, 2025EPS Estimate
2.16Last Dividend Ex-Date
Sep 15, 2025Dividend Yield2.8%
Share Statistics
EPS (TTM)2.01
Shares Outstanding1,240,806,900
10 Day Avg. Volume7,105,949
30 Day Avg. Volume6,175,887
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue5.46
Enterprise Value/Gross Profit6.95
Enterprise Value/Ebitda14.35
Forecast
1Y Price Target
$128.10Price Target Upside14.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Bulls Say, Bears Say
Bulls Say
Patent And Legal PositionThe PTAB denied institution of Cipla's request for inter partes review of the '802 Patent in favor of Gilead, strengthening Gilead's patent position.
Product EndorsementsThe US CDC recently updated its HIV pre-exposure prophylaxis (PrEP) guidelines and now recommends GILD's Yeztugo as an option.
Revenue And EarningsThe company raised their full year revenue and EPS guides due to better than expected HIV performance.
Bears Say
Market Access UncertaintyThe timing of Health and Human Services action to mandate unrestricted access to Yeztugo remains uncertain.
Market DiversificationThe oncology and liver programs, while contributing to growth, are overshadowed by the dominant HIV portfolio, making diversification challenging.
Market ValuationThe growth outlook for Gilead is largely priced in, with limited room for rapid growth needed to support expansion from its $150B market cap.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $82.82 and its highest was $121.83 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $139.09B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Oct 23, 2025 which is in 24 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Aug 07, 2025. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 2.8%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 2.16.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,240,806,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.01 in its last earnings report, beating expectations of $1.96. Following the earnings report the stock price went up 8.282%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$128.10 (14.27% Upside)
$128.10 (14.27% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.01%
12-Months-Change
Fundamentals
Return on Equity
33.26%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that focuses on the discovery, development, and commercialization of innovative medicines. The company primarily operates in the fields of antiviral therapeutics, particularly for HIV/AIDS, hepatitis B, hepatitis C, and influenza, alongside therapies for oncology, inflammatory diseases, and other serious conditions. Gilead's core products include its flagship antiviral drugs, such as Biktarvy, Descovy, and Harvoni, as well as emerging therapies in its diverse pipeline.
GILD Company Deck
GILD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Gilead with significant achievements, including the FDA approval of Yeztugo and strong sales growth in the HIV segment. However, there are challenges with declining Veklury sales and competition in cell therapy, along with potential policy impacts. Overall, the highlights significantly outweigh the lowlights, indicating a strong position for Gilead moving forward.View all GILD earnings summariesGILD Revenue Breakdown
68.21% HIV
11.44% Oncology
10.51% Liver Disease
6.26% Veklury
3.59% Other
GILD Stock 12 Month Forecast
Average Price Target
$128.10
▲(14.27% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
30.74% Mutual Funds
18.63% Other Institutional Investors
23.98% Public Companies and Individual Investors